Cargando…
Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; i...
Autores principales: | Bendix, Mia, Dige, Anders, Jørgensen, Søren Peter, Dahlerup, Jens Frederik, Bibby, Bo Martin, Deleuran, Bent, Agnholt, Jørgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759913/ https://www.ncbi.nlm.nih.gov/pubmed/33266022 http://dx.doi.org/10.3390/nu12123699 |
Ejemplares similares
-
Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn’s Disease during One-Year Follow-Up
por: Bendix, Mia, et al.
Publicado: (2021) -
Vitamin D increases programmed death receptor-1 expression in Crohn’s disease
por: Bendix, Mia, et al.
Publicado: (2017) -
Effects of Anti-TNFα Treatment on Mucosal Expression of IL-17A, IL-21, and IL-22 and Cytokine-Producing T Cell Subsets in Crohn's Disease
por: Dige, Anders, et al.
Publicado: (2018) -
Infliximab Induces Clonal Expansion of γδ-T Cells in Crohn's Disease: A Predictor of Lymphoma Risk?
por: Kelsen, Jens, et al.
Publicado: (2011) -
Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients
por: Bjerg Christensen, Ane, et al.
Publicado: (2015)